Bullish Case: Known: PSNL at $9.61, after a sharp -20.6% week. Inferred: PSNL return-surface likelihood clusters around modest +10–+60% outcomes for ~0–2yr holds; extreme +300% tails look thin. Uncertain: MRD-to-revenue cadence. EU CE-IVD blood-kit milestone + Medicare/CMS expansion support adoption. Earlier “rapid +80%” didn’t fit; partial rerate did (+90d), so upside remains plausible if guidance impresses and SPY-IV stops worsening.

Bearish Case: Known: put volume is ~6xx% vs calls today; also PSNL is still down sharply vs last week. Inferred: SPY-IV surface stays elevated across near-term days/strikes (mid-20s to low-30s), raising odds of fast risk-off drawdowns. Uncertain: whether MRD uptake converts before any dilution/guide reset. PSNL return-surface shows meaningful left-tail mass (downside tails aren’t zero). Prior bearish “-25–-60%” wasn’t realized yet; it remains a tail risk.

Potential Outcomes:

1. 35% +10–+30% (modest rerate): MRD adoption and Medicare/CMS durability; aligns with thick return-surface band. Oracle lens: this is likelier if SPY-IV cools vs current skew.
2. 25% -15–+20% range: flat guidance/slow ordering; IV stays high so price mean-reverts.
3. 20% +40–+100%: guidance upgrade + partner/coverage signal amplifies rerate.
4. 12% -25–-50%: dilution or missed revenue cadence around next earnings.
5. 5% -15–-30%: macro/vol spike triggers oncology selloff.
6. 3% -50%+: reimbursement/clinical shock.

June 11, 2026